Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland

Abstract

Background Evidence from controlled trials has shown that lanreotide autogel is effective in achieving biochemical and symptom control in patients with acromegaly. However, it is important to better understand the real-world patient population receiving lanreotide autogel treatment.

Methods In this non-interventional study the long-term treatment response to lanreotide autogel in adult patients with acromegaly from office-based centers or clinics in Germany, Austria and Switzerland was studied. Assessments included growth hormone and insulin-like growth factor-I levels, symptoms, quality of life, lanreotide plasma levels and tumor somatostatin receptor subtype expression. The primary endpoint was achievement of full biochemical control, defined as growth hormone ≤2.5 µg/L and insulin-like growth factor I normalization at month 12.

Results 76 patients were enrolled from 21 sites. 7/51 (13.7%) patients of the efficacy population had full biochemical control at baseline, 15/33 (45.5%) at month 12 and 10/26 (38.5%) at month 24 of treatment. At 12 months of treatment higher rates of biochemical control were observed in the following subgroups: older patients (>53 years [median]), females, treatment-naïve patients, and patients with a time since diagnosis of longer than 1.4 years (median). No clinically relevant differences in acromegaly symptoms or quality of life scores were observed. Median fasting blood glucose and glycated hemoglobin levels remained unchanged throughout the study. No new safety signals were observed. Overall tolerability of treatment with lanreotide autogel was judged by 80.8% of the enrolled patients at month 12 as ‘very good’ or ‘good’.

Conclusion Treatment with lanreotide autogel in a real-world setting showed long-term effectiveness and good tolerability in patients with acromegaly.

Key words

acromegaly - lanreotide autogel - insulin-like growth factor I - growth hormone - biochemical control - symptoms

Publikationsverlauf

Eingereicht: 29. April 2020
Eingereicht: 31. Juli 2020

Angenommen: 25. August 2020

Artikel online veröffentlicht:
07. Dezember 2020

• References

• 1 Chanson P, Salenave S, Kamenicky P. et al. Pituitary tumours: Acromegaly. Best Pract Res Clin Endocrinol Metab 2009; 23: 555-574
• 2 Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999; 2: 29-41
• 3 Nachtigall L, Delgado A, Swearingen B. et al. Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 2008; 93: 2035-2041
• 4 Reid TJ, Post KD, Bruce JN. et al. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: Acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 2010; 72: 203-208
• 5 Katznelson L, Laws ER, Melmed S. et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
• 6 Melmed S, Bronstein MD, Chanson P. et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 2018; 14: 552-561
• 7 Caron P, Bex M, Cullen DR. et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 2004; 60: 734-740
• 8 Maiza JC, Vezzosi D, Matta M. et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007; 67: 282-289
• 9 Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93: 2957-2968
• 10 Carmichael JD, Bonert VS, Nuno M. et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: A meta-analysis. J Clin Endocrinol Metab 2014; 99: 1825-1833
• 11 Giustina A, Chanson P, Kleinberg D. et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 2014; 10: 243-248
• 12 Grozinsky-Glasberg S, Shimon I, Korbonits M. et al. Somatostatin analogues in the control of neuroendocrine tumours: Efficacy and mechanisms. Endocr Relat Cancer 2008; 15: 701-720
• 13 Schopohl J, Strasburger CJ, Caird D. et al. Efficacy and acceptability of lanreotide Autogel(R) 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 2011; 119: 156-162
• 14 Ronchi CL, Boschetti M, Degli Uberti EC. et al. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): An open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007; 67: 512-519
• 15 Attanasio R, Baldelli R, Pivonello R. et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 2003; 88: 5258-5265
• 16 Chanson P, Leselbaum A, Blumberg J. et al. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary 2000; 2: 269-276
• 17 Giusti M, Gussoni G, Cuttica CM. et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. J Clin Endocrinol Metab 1996; 81: 2089-2097
• 18 Amato G, Mazziotti G, Rotondi M. et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002; 56: 65-71
• 19 Caron PJ, Bevan JS, Petersenn S. et al. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary 2016; 19: 149-157
• 20 Caron PJ, Bevan JS, Petersenn S. et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: Results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 2014; 99: 1282-1290
• 21 Johns MW. A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep 1991; 14: 540-545
• 22 Webb SM, Prieto L, Badia X. et al. Acromegaly quality of life questionnaire (AcroQoL), a new health-related quality of life questionnaire for patients with acromegaly: Development and psychometric properties. Clin Endocrinol (Oxf) 2002; 57: 251-258
• 23 Giustina A, Chanson P, Bronstein MD. et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010; 95: 3141-3148
• 24 Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2011; 96: 1327-1335
• 25 Petersenn S, Schopohl J, Barkan A. et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: A randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010; 95: 2781-2789
• 26 Chanson P, Borson-Chazot F, Kuhn JM. et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 2008; 69: 299-305
• 27 Lombardi G, Minuto F, Tamburrano G. et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 2009; 32: 202-209
• 28 Melmed S, Cook D, Schopohl J. et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: A randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010; 13: 18-28
• 29 Petersenn S, Buchfelder M, Gerbert B. et al. Age and sex as predictors of biochemical activity in acromegaly: Analysis of 1485 patients from the German Acromegaly Register. Clin Endocrinol (Oxf) 2009; 71: 400-405
• 30 Colao A, Auriemma RS, Lombardi G. et al. Resistance to somatostatin analogs in acromegaly. Endocr Rev 2011; 32: 247-271
• 31 Ribeiro-Oliveira A, Abrantes MM, Barkan AL. Complex rhythmicity and age dependence of growth hormone secretion are preserved in patients with acromegaly: Further evidence for a present hypothalamic control of pituitary somatotropinomas. J Clin Endocrinol Metab 2013; 98: 2959-2966
• 32 Suliman M, Jenkins R, Ross R. et al. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest 1999; 22: 409-418
• 33 Colao A, Pivonello R, Cappabianca P. et al. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf) 2005; 63: 342-349
• 34 Salvatori R, Gordon MB, Woodmansee WW. et al. A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. Pituitary 2017; 20: 605-618
• 35 Arafat AM, Mohlig M, Weickert MO. et al. Growth hormone response during oral glucose tolerance test: The impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 2008; 93: 1254-1262
• 36 Yamamoto H, Kato Y. Relationship between plasma insulin-like growth factor I (IGF-I) levels and body mass index (BMI) in adults. Endocr J 1993; 40: 41-45
• 37 Colao A, Auriemma RS, Pivonello R. et al. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 2016; 19: 235-247
• 38 Taboada GF, Luque RM, Neto LV. et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 2008; 158: 295-303
• 39 Jaquet P, Saveanu A, Gunz G. et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000; 85: 781-792
• 40 Casarini AP, Jallad RS, Pinto EM. et al. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 2009; 12: 297-303
• 41 Wildemberg LE, Neto LV, Costa DF. et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest 2013; 36: 38-43
• 42 Venegas-Moreno E, Vazquez-Borrego MC, Dios E. et al. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med 2018; 22: 1640-1649
• 43 Casar-Borota O, Heck A, Schulz S. et al. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab 2013; 98: E1730-E1739
• 44 Takei M, Suzuki M, Kajiya H. et al. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: Good correlation with preoperative response to octreotide. Endocr Pathol 2007; 18: 208-216
• 45 Davi MV, Dalle Carbonare L, Giustina A. et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 2008; 159: 533-540
• 46 Wassenaar MJ, Biermasz NR, van Duinen N. et al. High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: A case-control study. Eur J Endocrinol 2009; 160: 357-365
• 47 Kyriakakis N, Lynch J, Gilbey SG. et al. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study. Clin Endocrinol (Oxf) 2017; 86: 806-815
• 48 Webb SM, Badia X, Surinach NL. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: A 6-month prospective study. Eur J Endocrinol 2006; 155: 269-277
• 49 Schofl C, Franz H, Grussendorf M. et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol 2013; 168: 39-47
• 50 Giustina A, Mazziotti G, Cannavo S. et al. High-dose and high-frequency lanreotide autogel in acromegaly: A randomized, multicenter study. J Clin Endocrinol Metab 2017; 102: 2454-2464
• 51 Puig-Domingo M, Soto A, Venegas E. et al. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study. Endocrinol Nutr 2016; 63: 397-408
• 52 Schofl C, Grussendorf M, Honegger J. et al. Failure to achieve disease control in acromegaly: Cause analysis by a registry-based survey. Eur J Endocrinol 2015; 172: 351-356
• 53 Burness CB, Dhillon S, Keam SJ. Lanreotide autogel((R)): A review of its use in the treatment of patients with acromegaly. Drugs 2014; 74: 1673-1691
• 54 Schreiber I, Buchfelder M, Droste M. et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007; 156: 75-82